listado de los nuevos medicamentos(Nuevo escáner de drogas)
Publicado: Jue Feb 13, 2014 7:40 pm
Nuevo escáner de medicamentos empleados para luchar contra el MM
Fuente:MyelomaUK
http://translate.google.es/translate?hl ... annel%3Dfs
Filtro
Tipo de fármaco:
Buscar:
Drug name Brand name Company Type Phase
**4SC-202 4SC AG Histone deacetylase inhibitor I / II
4SC-202 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
**ABT-199 Genentech Bcl-2 inhibitor I
ABT-199 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as bcl-2 inhibitors
**ALT-801 Altor Bioscience Immunotherapy II
ALT-801 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as immunotherapeutics.
**Amrubicin Calsed Celgene Corporation Chemotherapy II
Amrubicin is a chemotherapy agent used to treat many different cancers. It is being tested as a treatment for myeloma.
**Aplidin Aplidin PharmaMar New molecular entity II / III
Plitidepsin is a novel anti-cancer drug of marine origin that is being investigated for as a treatment for myeloma.
**AR-42 Arno Therapeutics Pan-deacetylase inhibitor I / II
AR-42 is a new drug being investigated for the treatment of myeloma. It is a broad spectrum histone and non-histone deacetylase (pan-deacetylase) inhibitor.
**ARRY-520 Array Biopharma Kinesin spindle inhibitor I / II
ARRY-520 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as kinesin spindle inhibitors.
**Azacitidine Vidaza Celgene Corporation Chemotherapy II
Azacitidine is a chemotherapy drug used in the treatment of blood cell disorders and cancers. It is being tested as a treatment for myeloma.
++Bendamustine Levact; Treanda; Ribomustin Napp Pharmaceuticals Chemotherapy III
Bendamustine is a chemotherapy drug used to treat myeloma and other cancers.
++BI-505 BioInvent International AB Monoclonal antibody II
BI-505 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++BMS-936564 Bristol Myers Squibb Monoclonal antibody I / II
BMS-936564 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Bortezomib Velcade Janssen Proteasome inhibitor II / III
Velcade is the first in a new class of anti-cancer drugs called proteasome inhibitors.
++Brentuximab Adcetris Seattle Genetics Antibody-drug conjugate II
Brentuximab is a new drug being investigated for the treatment of myeloma and other cancers. It belongs to a class of drugs known as antibody-drug conjugates
++BT-062 Biotest AG Antibody-drug conjugate II
BT062 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as antibody-drug conjugates.
++Cabozantinib Cometriq Exelixis Inc. Tyrosine kinase inhibitor II
Cabozantinib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Carfilzomib Kyprolis (US) Onyx Pharmaceuticals Proteasome inhibitor II / III
Carfilzomib is a new proteasome inhibitor which works in a similar way to Velcade. It is thought to be more potent but better tolerated than Velcade.
++CC-115 Celgene Corporation Dual DNA-protein kinase mTOR inhibitor I / II
CC-115 is a new drug being tested as a treatment for myeloma. It belongs to a new class of experimental drugs known as dual DNA protein kinase and mammalian target of rapamycin (mTOR) inhibitors
++CC-122 Celgene Corporation IMiD I / II
CC-122 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as immunomodulatory drugs.
++CC-223 Celgene Corporation mTOR inhibitor II
CC-223 is a new drug being investigated for the treatment if myeloma. It belongs to a class of drugs known as mTOR inhibitors.
++Cisplatin Cisplatin Off patent Chemotherapy III
Cisplatin is a chemotherapy drug used to treat myeloma and other cancers.
++CUDC-907 Curis Inc Multi-targeted drug I / II
CUDC-907 is a new drug being tested as a treatment for myeloma. It works by targeting multiple mechanisms within the myeloma cell.
++Cyclophosphamide Off patent Chemotherapy III
Cyclophosphamide is a chemotherapy drug used to treat myeloma and other cancers.
++Daratumumab Janssen Biotech/Genmab Monoclonal antibody II
Daratumumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Dasatinib Sprycel Bristol Myers Squibb Tyrosine kinase inhibitor II
Dasatinib is a new drug being investigated for the treatment of myeloma and other blood cancers. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Denosumab Xgeva Amgen Monoclonal antibody II / III
Denosumab is a new drug that helps to reduce bone breakdown.
++Dexamethasone Decadron Off patent Steroid III
Dexamethasone is a steroid drug which is given alone or in conbination with other drugs in the treatment of myeloma.
++DFRF4539A Genentec Inc. Antibody-drug conjugate I / II
DFRF4539A is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as antibody-drug conjugates
++Dinaciclib Schering-Plough Cyclin-dependent kinase inhibitor I / II
Dinaciclib is a new drug being investigated for the treatment of myeloma. It belongs to class of drugs known as cyclin-dependent kinase (CDK) inhibitors.
++DKN-01 Dekkun Corporation Monoclonal antibody II
DKN-01 is a new drug being investigated for the treatment of myeloma bone disease. It belongs to a class of drugs known as monoclonal antibodies.
++Doxorubicin Adriamycin; Doxil Chemotherapy III
Adriamycin is a chemotherapy drug used to treat myeloma and other cancers
++Elotuzumab Bristol Myers Squibb Monoclonal antibody II / III
Elotuzumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Etoposide Etoposide Off patent Chemotherapy III
Etoposide is a chemotherapy drug used to treat myeloma and other cancers
++Everolimus Affinitor Novartis mTOR inhibitor II
Everolimus is an anti-cancer drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as mammalian target of rapamycin (mTOR) inhibitors
++Ganetespib Synta Pharmaceuticals Heat shock protein inhibitor I / II
Ganetespib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as heat shock protein inhibitors.
++GSK2110183 GlaxoSmithKline AKT inhibitor I / II
GSK2110183 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as AKT inhibitors
++Ibrutinib Pharmacyclics Bruton's tyrosine kinase inhibitor II
brutinib is a new drug being investigated for the treatment for myeloma and other blood cancers. It belongs to a class of drugs known as Bruton's tyrosine kinase inhibitor.
++Ixazomib Millenium-Takeda Proteasome inhibitor II / III
Ixazomib is a new proteasome inhibitor which works in a similar way to Velcade and carfilzomib. It is the first oral proteasome inhibitor being tested in myeloma.
++Lenalidomide Revlimid Celgene Corporation IMiD III
Revlimid is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++LGH-447 Novartis PIM kinase inhibitor I
LGH-447 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as Pim kinase inhibitors
++Linsitinib Astellas Pharma Insulin-like growth factor inhibitor II
Linsitinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as insulin-like growth factor inhibitors.
++Marizomib Neureus Pharmaceuticals Proteasome inhibitor I / II
Marizomib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as proteasome inhibitors.
++Masitinib AB Science Tyrosine kinase inhibitor II / III
Masitinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKI).
++Melflufen Oncopeptides AB Chemotherapy II
Melflufen is a modified version of the chemotherapy drug melphalan.
++Melphalan Alkeran Off ptent Chemotherapy III
Melphalan is a chemotherapy drug used to treat myeloma and other cancers.
++MLN 9708 Proteasome Inhibitor III
MLN 9708 is the first oral proteasome inhibitor to be tested in myeloma and is thought to potentially be more effective and associated with fewer side-effects (e.g. peripheral neuropathy) than Velcade.
++MOR202 Morphosys Monoclonal antibody II
MOR202 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Nelfinavir Viracept Viv Healthcare Protease inhibitor II
Nelfinavir is an anti-retroviral drug originally used in the treatment of HIV. It belongs to a class of drugs known as protease inhibitors and is being tested as a treatment for myeloma.
++Nivolumab Bristol Myers Squibb Monoclonal antibody I / II
Nivolumab is a new drug being tested as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as proteasome inhibitors.
++NOX-A12 Noxxon Pharma AG Monoclonal antibody II
NOX-A12 is a new drug being investigated as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as monoclonal antibodies
++Oprozomib Onyx Pharmaceuticals Proteasome inhibitor II
Oprozomib is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as proteasome inhibitors.
++Panobinostat Novartis HDAC inhibitor II
Panobinostat is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors
++PAT-SM6 Patrys Ltd Monoclonal antibody I / II
PAT-SM6 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Plerixafor Mozobil Sanofi-Aventis Immunostimulant III
Mozobil is an immunostimulant used to help mobilise stem cells from the bone marrow
++Pomalidomide Pomalyst (US) Imnovid (Europe) Celgene Corporation IMiD III
Pomalidomide is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++Pralatrexate Folotyn Allos Therapeutics Inc Metabolic inhibitors I / II
Pralatrexate is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as metabolic inhibitors, specifically an anti-folate.
++PRLX 93936 Prolexys Pharmaceuticals RAS inhibitor II
PRLX 93936 is a new drug being tested for the treatment of myeloma. It is a small molecule anti-cancer treatment that specifically targets the ras protein.
++PVX-410 Oncopep Vaccine II
PVX-410 is a vaccine that is being tested as a treatment for myeloma.
++Roclinostat Acetylon Pharmaceuticals HDAC inhibitor II
Roclinostat is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++Romidepsin Istodax Celgene Corporation HDAC inhibitor II
Romidepsin is a new drug being investigated for the treatment of myeloma and other blood cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++SAR650984 Sanofi-Aventis Monoclonal antibody I / II
SAR650984 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies
++Siltuximab Centocor Monoclonal antibody III
Siltuximab is a monoclonal antibody which targets the cytokine interleukin 6 (IL 6), one of the major stimulators of myeloma cell grwoth. Removing IL 6 significantly slows down the rate of myeloma cell growth.
++SNS01-T Senesco Technologies Inc. Nanoparticle therapy II
SNS01-T is a new drug being tested as a treatment for myeloma and other blood cancers. It represents a new approach to treatment involving the use of nanoparticle technology.
++Sotatercept Celgene Corporation Recombinant protein I / II
Sotatercept is a new drug being investigated for the treatment of myeloma bone disease.
++Tabalumab Eli Lilly Monoclonal antibody II
Tabalumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs knnown as monoclonal antibodies.
++TH-302 Threshold Pharmaceuticals Hypoxia-activated pro-drug II
TH-302 is a new drug being tested as a treatment for myeloma and other cancers. It is a drug designed to be activated under conditions of low oxygen (hypoxia), a hallmark of many cancers.
++Thalidomide Thalidomide Celgene Celgene Corporation IMiD III
Thalidomide belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++Tivantinib Daiichi Sankyo Tyrosine kinase inhibitor II
Tivantinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Veliparib Abbott PARP inhibitor I / II
Veliparib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as PARP inhibitors.
++Vemurafenib Zelboraf Daiichi Sankyo B-Raf inhibitor I
Vemurafenib is a new drug being tested for the treatment of myeloma and other cancer patients who specifically have the BRAF V600E mutation.
++Vorinostat Zolinza Merck & Co HDAC inhibitor II / III
Vorinostat is a new drug being investigated for the treatment of myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++WT-1 vaccine Memorial Sloan-Kettering Cancer Centre Vaccine I / II
WT-1 is a vaccine that is being tested as a treatment for myeloma.
Vaya lista mas larga!
Es muy alentador ver que hay tantas opciones de tratamiento para el MM!
Fuente:MyelomaUK
http://translate.google.es/translate?hl ... annel%3Dfs
Filtro
Tipo de fármaco:
Buscar:
Drug name Brand name Company Type Phase
**4SC-202 4SC AG Histone deacetylase inhibitor I / II
4SC-202 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
**ABT-199 Genentech Bcl-2 inhibitor I
ABT-199 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as bcl-2 inhibitors
**ALT-801 Altor Bioscience Immunotherapy II
ALT-801 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as immunotherapeutics.
**Amrubicin Calsed Celgene Corporation Chemotherapy II
Amrubicin is a chemotherapy agent used to treat many different cancers. It is being tested as a treatment for myeloma.
**Aplidin Aplidin PharmaMar New molecular entity II / III
Plitidepsin is a novel anti-cancer drug of marine origin that is being investigated for as a treatment for myeloma.
**AR-42 Arno Therapeutics Pan-deacetylase inhibitor I / II
AR-42 is a new drug being investigated for the treatment of myeloma. It is a broad spectrum histone and non-histone deacetylase (pan-deacetylase) inhibitor.
**ARRY-520 Array Biopharma Kinesin spindle inhibitor I / II
ARRY-520 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as kinesin spindle inhibitors.
**Azacitidine Vidaza Celgene Corporation Chemotherapy II
Azacitidine is a chemotherapy drug used in the treatment of blood cell disorders and cancers. It is being tested as a treatment for myeloma.
++Bendamustine Levact; Treanda; Ribomustin Napp Pharmaceuticals Chemotherapy III
Bendamustine is a chemotherapy drug used to treat myeloma and other cancers.
++BI-505 BioInvent International AB Monoclonal antibody II
BI-505 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++BMS-936564 Bristol Myers Squibb Monoclonal antibody I / II
BMS-936564 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Bortezomib Velcade Janssen Proteasome inhibitor II / III
Velcade is the first in a new class of anti-cancer drugs called proteasome inhibitors.
++Brentuximab Adcetris Seattle Genetics Antibody-drug conjugate II
Brentuximab is a new drug being investigated for the treatment of myeloma and other cancers. It belongs to a class of drugs known as antibody-drug conjugates
++BT-062 Biotest AG Antibody-drug conjugate II
BT062 is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as antibody-drug conjugates.
++Cabozantinib Cometriq Exelixis Inc. Tyrosine kinase inhibitor II
Cabozantinib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Carfilzomib Kyprolis (US) Onyx Pharmaceuticals Proteasome inhibitor II / III
Carfilzomib is a new proteasome inhibitor which works in a similar way to Velcade. It is thought to be more potent but better tolerated than Velcade.
++CC-115 Celgene Corporation Dual DNA-protein kinase mTOR inhibitor I / II
CC-115 is a new drug being tested as a treatment for myeloma. It belongs to a new class of experimental drugs known as dual DNA protein kinase and mammalian target of rapamycin (mTOR) inhibitors
++CC-122 Celgene Corporation IMiD I / II
CC-122 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as immunomodulatory drugs.
++CC-223 Celgene Corporation mTOR inhibitor II
CC-223 is a new drug being investigated for the treatment if myeloma. It belongs to a class of drugs known as mTOR inhibitors.
++Cisplatin Cisplatin Off patent Chemotherapy III
Cisplatin is a chemotherapy drug used to treat myeloma and other cancers.
++CUDC-907 Curis Inc Multi-targeted drug I / II
CUDC-907 is a new drug being tested as a treatment for myeloma. It works by targeting multiple mechanisms within the myeloma cell.
++Cyclophosphamide Off patent Chemotherapy III
Cyclophosphamide is a chemotherapy drug used to treat myeloma and other cancers.
++Daratumumab Janssen Biotech/Genmab Monoclonal antibody II
Daratumumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Dasatinib Sprycel Bristol Myers Squibb Tyrosine kinase inhibitor II
Dasatinib is a new drug being investigated for the treatment of myeloma and other blood cancers. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Denosumab Xgeva Amgen Monoclonal antibody II / III
Denosumab is a new drug that helps to reduce bone breakdown.
++Dexamethasone Decadron Off patent Steroid III
Dexamethasone is a steroid drug which is given alone or in conbination with other drugs in the treatment of myeloma.
++DFRF4539A Genentec Inc. Antibody-drug conjugate I / II
DFRF4539A is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as antibody-drug conjugates
++Dinaciclib Schering-Plough Cyclin-dependent kinase inhibitor I / II
Dinaciclib is a new drug being investigated for the treatment of myeloma. It belongs to class of drugs known as cyclin-dependent kinase (CDK) inhibitors.
++DKN-01 Dekkun Corporation Monoclonal antibody II
DKN-01 is a new drug being investigated for the treatment of myeloma bone disease. It belongs to a class of drugs known as monoclonal antibodies.
++Doxorubicin Adriamycin; Doxil Chemotherapy III
Adriamycin is a chemotherapy drug used to treat myeloma and other cancers
++Elotuzumab Bristol Myers Squibb Monoclonal antibody II / III
Elotuzumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Etoposide Etoposide Off patent Chemotherapy III
Etoposide is a chemotherapy drug used to treat myeloma and other cancers
++Everolimus Affinitor Novartis mTOR inhibitor II
Everolimus is an anti-cancer drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as mammalian target of rapamycin (mTOR) inhibitors
++Ganetespib Synta Pharmaceuticals Heat shock protein inhibitor I / II
Ganetespib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as heat shock protein inhibitors.
++GSK2110183 GlaxoSmithKline AKT inhibitor I / II
GSK2110183 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as AKT inhibitors
++Ibrutinib Pharmacyclics Bruton's tyrosine kinase inhibitor II
brutinib is a new drug being investigated for the treatment for myeloma and other blood cancers. It belongs to a class of drugs known as Bruton's tyrosine kinase inhibitor.
++Ixazomib Millenium-Takeda Proteasome inhibitor II / III
Ixazomib is a new proteasome inhibitor which works in a similar way to Velcade and carfilzomib. It is the first oral proteasome inhibitor being tested in myeloma.
++Lenalidomide Revlimid Celgene Corporation IMiD III
Revlimid is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++LGH-447 Novartis PIM kinase inhibitor I
LGH-447 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as Pim kinase inhibitors
++Linsitinib Astellas Pharma Insulin-like growth factor inhibitor II
Linsitinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as insulin-like growth factor inhibitors.
++Marizomib Neureus Pharmaceuticals Proteasome inhibitor I / II
Marizomib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as proteasome inhibitors.
++Masitinib AB Science Tyrosine kinase inhibitor II / III
Masitinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors (TKI).
++Melflufen Oncopeptides AB Chemotherapy II
Melflufen is a modified version of the chemotherapy drug melphalan.
++Melphalan Alkeran Off ptent Chemotherapy III
Melphalan is a chemotherapy drug used to treat myeloma and other cancers.
++MLN 9708 Proteasome Inhibitor III
MLN 9708 is the first oral proteasome inhibitor to be tested in myeloma and is thought to potentially be more effective and associated with fewer side-effects (e.g. peripheral neuropathy) than Velcade.
++MOR202 Morphosys Monoclonal antibody II
MOR202 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Nelfinavir Viracept Viv Healthcare Protease inhibitor II
Nelfinavir is an anti-retroviral drug originally used in the treatment of HIV. It belongs to a class of drugs known as protease inhibitors and is being tested as a treatment for myeloma.
++Nivolumab Bristol Myers Squibb Monoclonal antibody I / II
Nivolumab is a new drug being tested as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as proteasome inhibitors.
++NOX-A12 Noxxon Pharma AG Monoclonal antibody II
NOX-A12 is a new drug being investigated as a treatment for myeloma and other blood cancers. It belongs to a class of drugs known as monoclonal antibodies
++Oprozomib Onyx Pharmaceuticals Proteasome inhibitor II
Oprozomib is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as proteasome inhibitors.
++Panobinostat Novartis HDAC inhibitor II
Panobinostat is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors
++PAT-SM6 Patrys Ltd Monoclonal antibody I / II
PAT-SM6 is a new drug being tested for the treatment of myeloma. It belongs to a class of drugs known as monoclonal antibodies.
++Plerixafor Mozobil Sanofi-Aventis Immunostimulant III
Mozobil is an immunostimulant used to help mobilise stem cells from the bone marrow
++Pomalidomide Pomalyst (US) Imnovid (Europe) Celgene Corporation IMiD III
Pomalidomide is a derivative of thalidomide and belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++Pralatrexate Folotyn Allos Therapeutics Inc Metabolic inhibitors I / II
Pralatrexate is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as metabolic inhibitors, specifically an anti-folate.
++PRLX 93936 Prolexys Pharmaceuticals RAS inhibitor II
PRLX 93936 is a new drug being tested for the treatment of myeloma. It is a small molecule anti-cancer treatment that specifically targets the ras protein.
++PVX-410 Oncopep Vaccine II
PVX-410 is a vaccine that is being tested as a treatment for myeloma.
++Roclinostat Acetylon Pharmaceuticals HDAC inhibitor II
Roclinostat is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++Romidepsin Istodax Celgene Corporation HDAC inhibitor II
Romidepsin is a new drug being investigated for the treatment of myeloma and other blood cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++SAR650984 Sanofi-Aventis Monoclonal antibody I / II
SAR650984 is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as monoclonal antibodies
++Siltuximab Centocor Monoclonal antibody III
Siltuximab is a monoclonal antibody which targets the cytokine interleukin 6 (IL 6), one of the major stimulators of myeloma cell grwoth. Removing IL 6 significantly slows down the rate of myeloma cell growth.
++SNS01-T Senesco Technologies Inc. Nanoparticle therapy II
SNS01-T is a new drug being tested as a treatment for myeloma and other blood cancers. It represents a new approach to treatment involving the use of nanoparticle technology.
++Sotatercept Celgene Corporation Recombinant protein I / II
Sotatercept is a new drug being investigated for the treatment of myeloma bone disease.
++Tabalumab Eli Lilly Monoclonal antibody II
Tabalumab is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs knnown as monoclonal antibodies.
++TH-302 Threshold Pharmaceuticals Hypoxia-activated pro-drug II
TH-302 is a new drug being tested as a treatment for myeloma and other cancers. It is a drug designed to be activated under conditions of low oxygen (hypoxia), a hallmark of many cancers.
++Thalidomide Thalidomide Celgene Celgene Corporation IMiD III
Thalidomide belongs to a class of drugs called immunomodulatory drugs (IMiDs).
++Tivantinib Daiichi Sankyo Tyrosine kinase inhibitor II
Tivantinib is a new drug being investigated for the treatment of myeloma. It belongs to a class of drugs known as tyrosine kinase inhibitors.
++Veliparib Abbott PARP inhibitor I / II
Veliparib is a new drug being tested as a treatment for myeloma. It belongs to a class of drugs known as PARP inhibitors.
++Vemurafenib Zelboraf Daiichi Sankyo B-Raf inhibitor I
Vemurafenib is a new drug being tested for the treatment of myeloma and other cancer patients who specifically have the BRAF V600E mutation.
++Vorinostat Zolinza Merck & Co HDAC inhibitor II / III
Vorinostat is a new drug being investigated for the treatment of myeloma and other cancers. It belongs to a class of drugs known as histone deacetylase (HDAC) inhibitors.
++WT-1 vaccine Memorial Sloan-Kettering Cancer Centre Vaccine I / II
WT-1 is a vaccine that is being tested as a treatment for myeloma.
Vaya lista mas larga!
Es muy alentador ver que hay tantas opciones de tratamiento para el MM!
despues de leer el post de Fercu:"lo que funcciona y lo que no funcciona"..